Clinical Trial Update: Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating AM80 in combination with gemcitabine, cisplatin, and nivolumab for urothelial carcinoma; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma
• Urothelial Carcinoma of the Bladder
• Urothelial Carcinoma of the Renal Pelvis
• Urothelial Carcinoma of the Ureter
• Urothelial Carcinoma of the Urethra

Drugs mentioned

• AM80 (AM80)
• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• nivolumab (nivolumab)

Snippet

Sponsor: Nagoya University | Conditions: Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter | Phase 2 | Status: RECRUITING